ANGLE plc (GB:AGL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ANGLE plc has unveiled promising new data at the AACR Special Conference, highlighting its Parsortix-based PD-L1 assay’s potential in improving personalized treatment for lung cancer patients. This innovative liquid biopsy technology enables non-invasive, ongoing monitoring of PD-L1 status in circulating tumor cells, which could offer a more dynamic and comprehensive assessment of tumor heterogeneity compared to traditional tissue biopsies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.